29 April 2025 : Original article
Outcomes of Combined Liver-Kidney Transplantation in Polycystic Liver and Kidney Disease
Xiaojie Chen ABCDEF 1,2, Yida Lu
ABCDEF 1,2, Lin Wei CD 1,2, Li-ying Sun AB 1,3,2, Zhigui Zeng EF 1,2, Wei Qu CDE 1,2, Ying Liu CD 1,2,3, Zhijun Zhu AG 1,2*
DOI: 10.12659/AOT.947639
Ann Transplant 2025; 30:e947639
Table 1 Patients characteristics.
| Sex | Age (years) | MELD score | eGFR* (mL/min) | KT | Operation time (hours) | PHT (days) | Complications | Immunosuppressive regimen** | Follow-up times (days) | Status | eGFR** (mL/min) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 57 | 20 | 18.64 | Yes | 12.8 | 175 | Sepsis | FK | 175 | Expired | 17.18 |
| 2 | Female | 42 | 14 | 48.77 | Yes | 11.1 | 23 | Liver allograft rejection | FK+MS+GC | 478 | Alive | 79.03 |
| 3 | Female | 59 | 15 | 24.56 | Yes | 9.0 | 20 | No | FK+MS+GC | 592 | Alive | 49.29 |
| 4 | Female | 50 | 19 | 45.58 | No | 4.1 | 26 | No | FK+MMF | 1180 | Alive | 14.42 |
| 5 | Female | 40 | 9 | 120.36 | No | 6.7 | 16 | No | FK+MMF | 1262 | Alive | 124.43 |
| 6 | Female | 56 | 35 | 6.24 | Yes | 10.6 | 29 | No | FK+MMF+GC | 1434 | Alive | 53.23 |
| 7 | Female | 63 | 22 | 6.38 | Yes | 9.7 | 30 | No | FK | 1491 | Alive | 58.54 |
| 8 | Female | 53 | 27 | 9.37 | Yes | 11.3 | 13 | PTLDLiver allograft rejectionRenal allograft stones | FK | 2794 | Alive | 69.37 |
| 9 | Female | 45 | 21 | 23.37 | Yes | 10.4 | 39 | No | FK | 3252 | Alive | 75.68 |
| MELD – Model for End-Stage Liver Disease; eGFR – estimated glomerular filtration rate; KT – kidney transplantation; PHT – postoperative hospitalization time; FK – tacrolimus; MMF – mycophenolate mofetil; MS – mycophenolate sodium; GC – glucocorticoid; PTLD – post-transplant lymphoproliferative disorders. * Before transplantation; ** at the end of follow-up. | ||||||||||||